ライフサイエンスコーパス: mepolizumab

1 treatment trials the anti-(IL-5) therapeutic Mepolizumab).

2 racteristics associated with the response to mepolizumab.

3 152 to 250 mg mepolizumab, and 156 to 750 mg mepolizumab.

4 rences among groups given different doses of mepolizumab.

5 al of 3 infusions) of 0.55, 2.5, or 10 mg/kg mepolizumab.

6 n the bronchial mucosa, was maintained after mepolizumab.

7 th after a single intravenous 750-mg dose of mepolizumab.

8 ly to achieve important asthma outcomes with mepolizumab.

9 d by 61% in the group receiving subcutaneous mepolizumab.

10 opulation comprised 274 patients assigned to mepolizumab 100 mg and 277 assigned to placebo.

11 o receive a subcutaneous injection of either mepolizumab 100 mg or placebo, plus standard of care, ev

12 ouble-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO)

13 II trial, MEA115575) where subjects received mepolizumab (100 mg, n = 9) or placebo (n = 8), as six m

14 events occurred in seven patients receiving mepolizumab (14 events, including one death; mean [+/-SD

15 : 159 were assigned to placebo, 154 to 75 mg mepolizumab, 152 to 250 mg mepolizumab, and 156 to 750 m

16 reduced from 1.91 with placebo to 1.01 with mepolizumab (47% reduction; rate ratio [RR] 0.53, 95% CI

17 to receive one of three doses of intravenous mepolizumab (75 mg, 250 mg, or 750 mg) or matched placeb

18 e evaluated long-term safety and efficacy of mepolizumab (750 mg) in HES.

19 ed in BAL post SBP-Ag (299), decreased after mepolizumab (99), and increased in sputum after WLAC (36

20 Mepolizumab, a humanized monoclonal anti-IL-5 antibody,

21 Patients were assigned to receive mepolizumab, a humanized monoclonal antibody against int

22 Mepolizumab, a humanized monoclonal antibody that binds

23 ic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against inte

24 ion of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-

25 Mepolizumab administered either intravenously or subcuta

26 Despite reducing chronic OCS use, mepolizumab also resulted in similar reductions in exace

27 Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, ca

28 the hypereosinophilic syndrome have received mepolizumab, an anti-IL-5 monoclonal antibody, for as lo

29 Mepolizumab, an anti-interleukin-5 monoclonal antibody a

30 Mepolizumab, an anti-interleukin-5 monoclonal antibody,

31 Mepolizumab, an antibody against IL-5, reduces esophagea

32 n children with EoE and whether therapy with mepolizumab, an antibody against IL-5, reduces the numbe

33 RATIONALE: Mepolizumab, an IL-5-blocking antibody, reduces exacerba

34 192 (70%) of 273 patients who received mepolizumab and 207 (74%) of 278 who received placebo re

35 Of 1192 patients, 846 received mepolizumab and 346 received placebo.

36 on, with 68 participants assigned to receive mepolizumab and 68 to receive placebo.

37 to 61) among patients receiving intravenous mepolizumab and by 53% (95% CI, 37 to 65) among those re

38 ed by 32% in the group receiving intravenous mepolizumab and by 61% in the group receiving subcutaneo

39 an on-treatment serious adverse event in the mepolizumab and placebo groups, respectively; the most c

40 odies have been designed to neutralize IL-5 (mepolizumab and reslizumab).

41 New anti-IL-5 therapeutics, mepolizumab and reslizumab, were US Food and Drug Admini

42 the therapeutic niche of anti-interleukin-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibody therap

43 ebo, 154 to 75 mg mepolizumab, 152 to 250 mg mepolizumab, and 156 to 750 mg mepolizumab.

44 frequency, corticosteroid-sparing effect of mepolizumab, and development of antimepolizumab antibodi

45 ore and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce ai

46 Mepolizumab approximately halved exacerbations requiring

47 Mepolizumab arrests eosinophil maturation; however, the

48 These results add to and support the use of mepolizumab as a favourable add-on treatment option to s

49 ks was achieved in 95% of patients receiving mepolizumab, as compared with 45% of patients receiving

50 A greater effect of mepolizumab, as compared with placebo, on the annual rat

51 37 to 65) among those receiving subcutaneous mepolizumab, as compared with those receiving placebo (P

52 Mepolizumab at a dose of 100 mg was associated with a lo

53 ompared the glucocorticoid-sparing effect of mepolizumab (at a dose of 100 mg) with that of placebo a

54 Studies show that mepolizumab can reduce the frequency of clinically signi

55 will examine how evidence generated from the mepolizumab clinical development program showed that blo

56 e Test patient-reported outcome score in the mepolizumab compared with placebo groups.

57 All mepolizumab doses were combined and individual patient-l

58 lations of the two original studies, and all mepolizumab doses were combined for analysis.

59 In these studies, mepolizumab ( DREAM: 75 mg, 250 mg, or 750 mg intravenou

60 95% CI 31-61%; p<0.0001), 1.46 in the 250 mg mepolizumab group (39% reduction, 19-54%; p=0.0005), and

61 year in the placebo group, 1.24 in the 75 mg mepolizumab group (48% reduction, 95% CI 31-61%; p<0.000

62 n, 19-54%; p=0.0005), and 1.15 in the 750 mg mepolizumab group (52% reduction, 36-64%; p<0.0001).

63 cantly greater proportion of patients in the mepolizumab group compared with the placebo group no lon

64 d-dose stratum was 2.39 times greater in the mepolizumab group than in the placebo group (95% confide

65 type (462 patients) was 1.40 per year in the mepolizumab group versus 1.71 per year in the placebo gr

66 not occur in 47% of the participants in the mepolizumab group versus 81% of those in the placebo gro

67 xacerbations was 1.19 per year in the 100-mg mepolizumab group, 1.27 per year in the 300-mg mepolizum

68 polizumab group, 1.27 per year in the 300-mg mepolizumab group, and 1.49 per year in the placebo grou

69 The annualized relapse rate was 1.14 in the mepolizumab group, as compared with 2.27 in the placebo

70 point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in t

71 A total of 44% of the participants in the mepolizumab group, as compared with 7% of those in the p

72 ne in the glucocorticoid dose was 50% in the mepolizumab group, as compared with no reduction in the

73 reduced glucocorticoid dose, patients in the mepolizumab group, as compared with those in the placebo

74 s for exacerbations in the 100-mg and 300-mg mepolizumab groups versus the placebo group were 0.80 (9

75 greater in the intravenous and subcutaneous mepolizumab groups, respectively, than in the placebo gr

76 42 points and 0.44 points greater in the two mepolizumab groups, respectively, than in the placebo gr

77 orticoid therapy to maintain asthma control, mepolizumab had a significant glucocorticoid-sparing eff

78 oximately half the participants treated with mepolizumab had protocol-defined remission.

79 orted by the investigator as possibly due to mepolizumab in 3 subjects.

80 od eosinophil count and clinical efficacy of mepolizumab in patients with severe eosinophilic asthma

81 the effect of humanized monoclonal antibody mepolizumab in patients with severe eosinophilic asthma

82 We aimed to further assess mepolizumab in patients with severe eosinophilic asthma

83 biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma.

84 f an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic synd

85 Segmental challenge without mepolizumab induced a rise in circulating eosinophils, b

86 Seventy-eight subjects received 1 to 66 mepolizumab infusions each (including mepolizumab infusi

87 to 66 mepolizumab infusions each (including mepolizumab infusions received in the placebo-controlled

88 INTERPRETATION: Mepolizumab is an effective and well tolerated treatment

89 Active treatment was 75 mg intravenous mepolizumab (MENSA) or 100 mg subcutaneous mepolizumab (

90 s mepolizumab (MENSA) or 100 mg subcutaneous mepolizumab (MENSA, SIRIUS).

91 children treated with 0.55, 2.5, or 10 mg/kg mepolizumab monthly for 12 weeks followed by no treatmen

92 One hundred five patients received mepolizumab (n = 54) or placebo (n = 51).

93 Patients received 750 mg of intravenous mepolizumab or placebo every 4 weeks for a total of 6 do

94 with severe eosinophilic asthma treated with mepolizumab or placebo in addition to standard of care f

95 Patients received either intravenous mepolizumab or placebo while the prednisone dose was tap

96 lone or prednisone dose to receive 300 mg of mepolizumab or placebo, administered subcutaneously ever

97 Mepolizumab reduced airway eosinophil numbers but had a

98 In MENSA, mepolizumab reduced the rate of exacerbations by 57% (pr

99 Anti-IL-5 monoclonal antibody (mepolizumab) reduces baseline bronchial mucosal eosinoph

100 re eosinophilic asthma respond positively to mepolizumab regardless of prior use of omalizumab.

101 the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab).

102 sinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remi

103 Mepolizumab's safety profile was comparable with that of

104 Treatment of severe asthmatics with mepolizumab significantly attenuated blood eosinophils a

105 Treatment with 100 mg subcutaneous mepolizumab significantly attenuated systemic differenti

106 Mepolizumab significantly reduced the rate of exacerbati

107 Findings from previous studies showed that mepolizumab significantly reduces the rate of exacerbati

108 rticipated in a randomized clinical trial of mepolizumab (substudy of a larger GSK sponsored global p

109 ml greater in patients receiving intravenous mepolizumab than in those receiving placebo (P=0.02) and

110 l greater in patients receiving subcutaneous mepolizumab than in those receiving placebo (P=0.03).

111 eosinophils per high-power field [hpf] after mepolizumab therapy), and 77% of all subjects had decrea

112 ent with an anti-IL-5 neutralizing antibody (mepolizumab) to reduce airway eosinophilia.

113 opical corticosteroids who required surgery, mepolizumab treatment led to a greater reduction in the

114 Mepolizumab treatment led to significantly more accrued

115 Mepolizumab treatment resulted in a reduction of airway

116 Before mepolizumab treatment, bronchoalveolar lavage eosinophil

117 reductions in the rate of exacerbations with mepolizumab treatment.

118 We investigated whether anti-IL-5 (mepolizumab) treatment reduced esophageal mast cell accu

119 humanized, monoclonal antibody against IL-5 (mepolizumab) using a randomized double-blind, placebo-co

120 sought to assess the efficacy and safety of mepolizumab versus placebo for severe bilateral nasal po

121 The exacerbation rate reduction with mepolizumab versus placebo increased progressively from

122 Mepolizumab versus placebo showed significant improvemen

123 cebo) and nasopharyngitis (in 31 [11%] given mepolizumab vs 46 [17%] given placebo).

124 on of which were headache (in 45 [16%] given mepolizumab vs 59 [21%] given placebo) and nasopharyngit

125 s asthma in both groups (in three [1%] given mepolizumab vs nine [3%] given placebo).

126 ma control and quality of life improved with mepolizumab vs placebo in both studies independent of pr

127 n vivo, reduction of EOS in the airway using mepolizumab was associated with diminished IL-17 express

128 INTERPRETATION: Mepolizumab was associated with significant improvements

129 han 150 cells per muL, predicted efficacy of mepolizumab was reduced.

130 The safety profile of mepolizumab was similar to that observed in previous stu

131 The safety profile of mepolizumab was similar to that of placebo.

132 The safety profile of mepolizumab was similar to that of placebo.

133 Mepolizumab was well tolerated and effective as a long-t

134 line blood eosinophil counts and efficacy of mepolizumab we did a secondary analysis of data from two

135 peutic options include the anti-IL5 antibody mepolizumab, whose efficacy has been described in small